Objectives: A previous single-country pilot study indicated serum anti-GM2 and anti-GA1 anti-glycolipid antibodies as potential biomarkers for acute canine polyradiculoneuritis. This study aims to validate these findings in a large geographically heterogenous cohort. Materials and Methods: Sera from 175 dogs clinically diagnosed with acute canine polyradiculoneuritis, 112 dogs with other peripheral nerve, cranial nerve or neuromuscular disorders and 226 neurologically normal dogs were screened for anti-glycolipid antibodies against 11 common glycolipid targets to determine the immunoglobulin G anti-glycolipid antibodies with the highest combined sensitivity and specificity for acute canine polyradiculoneuritis. Results: Anti-GM2 anti-glycolipid antibodies reached the highest combined sensitivity and specificity (sensitivity: 65.1%, 95% confidence interval 57.6 to 72.2%; specificity: 90.2%, 95% confidence interval 83.1 to 95.0%), followed by anti-GalNAc-GD1a anti-glycolipid antibodies (sensitivity: 61.7%, 95% confidence interval 54.1 to 68.9%; specificity: 89.3%, 95% confidence interval 82.0 to 94.3%) and these anti-glycolipid antibodies were frequently present concomitantly. Anti-GA1 anti-glycolipid antibodies were detected in both acute canine polyradiculoneuritis and control animals. Both for anti-GM2 and anti-GalNAc-GD1a anti-glycolipid antibodies, sex was found a significantly associated factor with a female to male odds ratio of 2.55 (P=0.0096) and 3.00 (P=0.0198), respectively. Anti-GalNAc-GD1a anti-glycolipid antibodies were more commonly observed in dogs unable to walk (odds ratio 4.56; P=0.0076). Clinical Significance: Anti-GM2 and anti-GalNAc-GD1a immunoglobulin G anti-glycolipid antibodies represent serum biomarkers for acute canine polyradiculoneuritis.

Serum anti-GM2 and anti-GalNAc-GD1a IgG antibodies are biomarkers for acute canine polyradiculoneuritis / Halstead, S. K.; Gourlay, D. S.; Penderis, J.; Bianchi, E.; Dondi, M.; Wessmann, A.; Musteata, M.; Le Chevoir, M.; Martinez-Anton, L.; Bhatti, S. F. M.; Volk, H.; Mateo, I.; Tipold, A.; Ives, E.; Pakozdy, A.; Gutierrez-Quintana, R.; Brocal, J.; Whitehead, Z.; Granger, N.; Pazzi, P.; Harcourt-Brown, T.; Jose-Lopez, R.; Rupp, S.; Schenk, H. C.; Smith, P.; Gandini, G.; Menchetti, M.; Mortera-Balsa, V.; Rusbridge, C.; Tauro, A.; Cozzi, F.; Deutschland, M.; Tirrito, F.; Freeman, P.; Lowrie, M.; Jackson, M. R.; Willison, H. J.; Rupp, A.. - In: JOURNAL OF SMALL ANIMAL PRACTICE. - ISSN 0022-4510. - (2021). [10.1111/jsap.13439]

Serum anti-GM2 and anti-GalNAc-GD1a IgG antibodies are biomarkers for acute canine polyradiculoneuritis

Bianchi E.;Dondi M.;
2021

Abstract

Objectives: A previous single-country pilot study indicated serum anti-GM2 and anti-GA1 anti-glycolipid antibodies as potential biomarkers for acute canine polyradiculoneuritis. This study aims to validate these findings in a large geographically heterogenous cohort. Materials and Methods: Sera from 175 dogs clinically diagnosed with acute canine polyradiculoneuritis, 112 dogs with other peripheral nerve, cranial nerve or neuromuscular disorders and 226 neurologically normal dogs were screened for anti-glycolipid antibodies against 11 common glycolipid targets to determine the immunoglobulin G anti-glycolipid antibodies with the highest combined sensitivity and specificity for acute canine polyradiculoneuritis. Results: Anti-GM2 anti-glycolipid antibodies reached the highest combined sensitivity and specificity (sensitivity: 65.1%, 95% confidence interval 57.6 to 72.2%; specificity: 90.2%, 95% confidence interval 83.1 to 95.0%), followed by anti-GalNAc-GD1a anti-glycolipid antibodies (sensitivity: 61.7%, 95% confidence interval 54.1 to 68.9%; specificity: 89.3%, 95% confidence interval 82.0 to 94.3%) and these anti-glycolipid antibodies were frequently present concomitantly. Anti-GA1 anti-glycolipid antibodies were detected in both acute canine polyradiculoneuritis and control animals. Both for anti-GM2 and anti-GalNAc-GD1a anti-glycolipid antibodies, sex was found a significantly associated factor with a female to male odds ratio of 2.55 (P=0.0096) and 3.00 (P=0.0198), respectively. Anti-GalNAc-GD1a anti-glycolipid antibodies were more commonly observed in dogs unable to walk (odds ratio 4.56; P=0.0076). Clinical Significance: Anti-GM2 and anti-GalNAc-GD1a immunoglobulin G anti-glycolipid antibodies represent serum biomarkers for acute canine polyradiculoneuritis.
Serum anti-GM2 and anti-GalNAc-GD1a IgG antibodies are biomarkers for acute canine polyradiculoneuritis / Halstead, S. K.; Gourlay, D. S.; Penderis, J.; Bianchi, E.; Dondi, M.; Wessmann, A.; Musteata, M.; Le Chevoir, M.; Martinez-Anton, L.; Bhatti, S. F. M.; Volk, H.; Mateo, I.; Tipold, A.; Ives, E.; Pakozdy, A.; Gutierrez-Quintana, R.; Brocal, J.; Whitehead, Z.; Granger, N.; Pazzi, P.; Harcourt-Brown, T.; Jose-Lopez, R.; Rupp, S.; Schenk, H. C.; Smith, P.; Gandini, G.; Menchetti, M.; Mortera-Balsa, V.; Rusbridge, C.; Tauro, A.; Cozzi, F.; Deutschland, M.; Tirrito, F.; Freeman, P.; Lowrie, M.; Jackson, M. R.; Willison, H. J.; Rupp, A.. - In: JOURNAL OF SMALL ANIMAL PRACTICE. - ISSN 0022-4510. - (2021). [10.1111/jsap.13439]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11381/2905621
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact